ALB and lung cancer: The lung cancer animal model shows 8.7% and 21.05% reduction in fluorescent AGEs during the treatment with PFT-HSA-TFT-Cy7 at 1 μM and 3 μM; on the other hand, the PFT-Hcy-HSA-Cy7 shows 6.57% and 19.29% inhibition in fluorescent AGEs at 1 μM and 3 μM, respectively (Figure 4(a)).